Biolinq secures $100M in Series C funding for its intradermal glucose sensor to improve metabolic health in type 2 diabetes, led by Alpha Wave Ventures.
Apr 22, 2025•8 months ago
Amount Raised
$100 Million
San DiegoMedical DeviceHealth CareBiotechnologyInvestors
Aphelion CapitalFeatures CapitalTaisho PharmaceuticalHikma VenturesRiver Vest Venture PartnersLife Sci Venture PartnersM VenturesAxa Im AltsAlpha Wave Ventures
Description
Biolinq announced the successful completion of a $100 million Series C funding round to advance its wearable biosensor technology for type 2 diabetes. Alpha Wave Ventures led the round with support from various existing investors. The funding will help Biolinq pursue regulatory approval and enhance its commercial readiness efforts. The company's glucose sensor is still under investigation and not yet approved by the FDA.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech